PubMed

Premarket Clinical Evidence Strength and Recalls of High-Risk Therapeutic Medical Devices.

PMID：42566203 · 2026-08-07

M, a, r, y, a, m, , M, o, o, g, h, a, l, i, ;, , F, a, a, i, z, a, h, , A, r, s, h, a, d, ;, , V, i, n, a, y, , K, , R, a, t, h, i, ;, , K, u, s, h, a, l, , T, , K, a, d, a, k, i, a, ;, , A, l, e, x, a, n, d, e, r, , O, , E, v, e, r, h, a, r, t, ;, , J, o, s, e, p, h, , S, , R, o, s, s, ;, , S, a, n, k, e, t, , S, , D, h, r, u, v, a

期刊JAMA health forum

年份2026-08-07

PMID42566203

摘要

High-risk medical devices approved through the US Food and Drug Administration (FDA) premarket approval (PMA) pathway may be supported by limited premarket clinical evidence, leaving uncertainties about safety. Whether device, premarket clinical evidence, or regulatory characteristics are associated with subsequent device recalls is unknown. To examine the association between device, premarket clinical evidence, and regulatory characteristics and serious recalls among high-risk therapeutic devic

官方来源

在 PubMed 上查看 →

数据来自 PubMed / NCBI。有关全文和最新信息，请始终参阅官方记录。